ClinicalTrials.gg
CompletedNCT00438633Updated Jun 21, 2019Results posted

Comparison of Early and Late Therapy for Adults With Non-Operatively Treated Proximal Humerus Fractures

An observational study in Proximal Humeral Fractures, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-21.

Sponsored by Massachusetts General Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
63
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to compare two common ways of rehabilitating after proximal humerus fractures treated non-operatively.

Read the detailed description

Proximal humerus fractures with limited displacement and fractures that occur in older, less active or infirm patients are treated non-operatively. There is a general impression, supported by some data, that better function is obtained with immediate initiation of shoulder exercises. However, there is some concern that this may contribute to nonunion of the fracture and may be unnecessary. Some researchers have demonstrated better outcomes with immediate rehabilitation with pendulum movements. Others have shown similar functional outcomes when rehabilitation begins approximately a month after injury, or when radiographs show signs of bone healing, and this delay is associated with lower rates of non-union and malunion occurrence.

02

Conditions studied

  • Proximal Humeral Fractures

Browse trials for

Keywords

  • proximal humerus fracture
  • rehabilitation
  • non-operative treatment
  • DASH and Constant instruments
03

In context

Shoulder Fractures

109 studies on the registry are indexed under Shoulder Fractures; 27 are open to participants now.

This study's enrollment of 63 is below the median of 94 across 55 observational studies indexed under Shoulder Fractures.

Browse Shoulder Fractures studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,582 studies on the registry; 451 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from the MGH Hand and Upper Extremity or Trauma service

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female patients.
  • Any race
  • Older than 18y
  • Diagnosed with proximal humeral fracture clinically and confirmed by imaging studies: X rays and/or CT Scans.
  • Any type of proximal humeral fracture according to the Neer or AO classification system.
  • Patient should have received non-operative treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients younger than 18 y.
  • Patients with multiple other fractures.
  • Patients that have received surgical treatment including closed reduction and percutaneous fixation, open reduction and internal fixation (plates, screws, pins, tension wire bands, cerclage wiring and/or intramedullary nailing) and/or articular shoulder prosthesis.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
63 participants (actual)

Groups and cohorts

  • Early Therapy

    Subjects who begin therapy immediately after diagnosis of injury.

  • Late Therapy

    Subjects who delay therapy for 3 weeks after diagnosis of injury.

06

What researchers measure

Primary outcomes

  1. Shoulder Flexion

    We measured active forward flexion of the shoulder

    Time frame: 6 months

Secondary outcomes

  1. Shoulder Pain Likert Scores

    Rated on a scale of 0-10, where 0 is no pain and 10 is severe pain.

    Time frame: 3 months, 6 months

  2. External Rotation

    Time frame: 3 months, 6 months

  3. Abduction

    Time frame: 3 months, 6 months

  4. Disability of the Hand, Shoulder, and Arm Score

    Disability of the Hand, Shoulder, and Arm Score (DASH) is a measure of upper extremity physical function, with scores ranging from 0 to 100. A higher score indicates more physical impairment.

    Time frame: 3 months, 6 months

07

Results

Posted Jun 21, 2019

Participant flow

Participant flow — Overall Study
MilestoneEarly TherapyLate Therapy
Started3231
3-month follow-up2624
Completed1614
Not completed1617
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up1517

Outcome measures

PrimaryShoulder Flexion

We measured active forward flexion of the shoulder

Time frame:
6 months
Reported as:
Mean · Degrees
Shoulder Flexion
DegreesEarly TherapyLate Therapy
Shoulder Flexion150 ± 26146 ± 22
SecondaryShoulder Pain Likert Scores

Rated on a scale of 0-10, where 0 is no pain and 10 is severe pain.

Time frame:
3 months, 6 months
Reported as:
Mean · units on a scale
Shoulder Pain Likert Scores
units on a scaleEarly TherapyLate Therapy
NRS Pain, 3 months3 ± 23 ± 1
NRS Pain, 6 months2 ± 12 ± 3
SecondaryExternal Rotation
Time frame:
3 months, 6 months
Reported as:
Mean · Degrees
External Rotation
DegreesEarly TherapyLate Therapy
External Rotation, 3 months53 ± 3051 ± 21
External Rotation, 6 months70 ± 1766 ± 26
SecondaryAbduction
Time frame:
3 months, 6 months
Reported as:
Mean · Degrees
Abduction
DegreesEarly TherapyLate Therapy
Abduction, 3 months115 ± 43101 ± 41
Abduction, 6 months147 ± 27136 ± 33
SecondaryDisability of the Hand, Shoulder, and Arm Score

Disability of the Hand, Shoulder, and Arm Score (DASH) is a measure of upper extremity physical function, with scores ranging from 0 to 100. A higher score indicates more physical impairment.

Time frame:
3 months, 6 months
Reported as:
Mean · Units on a scale
Disability of the Hand, Shoulder, and Arm Score
Units on a scaleEarly TherapyLate Therapy
DASH, 3 months33 ± 2524 ± 15
DASH, 6 months18 ± 1214 ± 7

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Early Therapy0/26 (0%)0/26 (0%)0/26 (0%)
Late Therapy0/24 (0%)0/24 (0%)0/24 (0%)

Baseline characteristics

Baseline characteristics are assessed for all subjects completing 3-month follow-up.

Age, Continuous
Age, Continuous(Years)Early TherapyLate TherapyTotal
Mean63 ± 1362 ± 1263 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Early TherapyLate TherapyTotal
Female5914
Male211536
Injured Hand
Injured Hand(Participants)Early TherapyLate TherapyTotal
Dominant91221
Non-dominant171229
Non- or minimally displaced
Non- or minimally displaced(Participants)Early TherapyLate TherapyTotal
Yes221941
No459
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Handoll HH, Elliott J, Thillemann TM, Aluko P, Brorson S. Interventions for treating proximal humeral fractures in adults. Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD000434. doi: 10.1002/14651858.CD000434.pub5. PubMed 35727196 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00438633
Responsible party
Neal Chung-Jen Chen (Principal Investigator; Hand Service, Massachusetts General Hospital) — Principal investigator
First posted
Feb 22, 2007
Start date
Feb 2005
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Jun 21, 2019
Last update
Jun 21, 2019

Study contacts

Neal Chen, MD
principal investigator · Massachusetts General Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion